Dr. David Solomon, CEO, Pharnext is deploying their innovative drug discovery platform that uses genetic data, big data and AI to determine combinations that are novel and non-obvious to find treatments for rare diseases.  With a focus on Charcot-Marie-Tooth, a rare neurologic peripheral neuropathy with no current treatments, Pharnext is seeing their drug PXT3003 stabilize patients with CMT1A, strengthen nerve transduction and also cause significant clinical improvement. @pharnext #pharnext #drugdiscovery #CMT #PXT3003 Pharnext.com Download the transcript here